1.	Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy Phase: Phase III Type: Treatment Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: CRPC2, NCT00974311
2.	Determine the Effect of MDV3100 on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of MDV3100 to Identify Potential Predictors of Response or Resistance to Therapy Phase: Phase II Type: Treatment Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: CRPC-MDA-1, NCT01091103
3.	A Study to Test if MDV3100 is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9785-CL-0321, 2010-021287-16, NCT01302041
4.	A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: S-3100-1-01, MSKCC-07045, IRB #07-045, MEDIVATION-MSKCC-07045, NCT00510718
5.	Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MDV3100-06, NCT01565928